The Philadelphia-area biopharma company PhaseBio Pharmaceuticals has received the final $15 million of a $25 million investment to fund further testing of its lead drug, which focuses on hyperglycemia related to Type 2 diabetes.
The company, a spinoff from Duke University now operating in Malvern, Pennsylvania, announced the Series B financing in January just before it left Research Triangle Park.
The additional $15 million comes as PhaseBio begins testing its drug Glymera, a biopolymer that increases the impact of certain drugs so it cuts the amounts (and cost) needed. PhaseBio is focused primarily on diabetes, cardiovascular issues and metabolic disease. The company is embarking on Phase I and Phase II testing.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
PhaseBio CEO Chris Prior said in his company’s press release that it will file next year a second investigational new drug application for Vasomera, which treats hypertension.
PhaseBio investors include New Enterprise Associates, OSI Investment Management, Hatteras Venture Partners, Johnson & Johnson Development Corporation and Fletcher Spaght Ventures.
Related articles
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
